CoChat
Sign Up
Cited by 60

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

In vivo cyclic induction of the FOXM1 transcription factor delays natural and progeroid aging phenotypes and extends healthspan

Ribeiro, Rui, Macedo, Joana C., Costa, Madalena, Ustiyan, Vladimir, Shindyapina, Anastasia V., Tyshkovskiy, Alexander, Gomes, Rita N., Castro, José Pedro, Kalin, Tanya V., Vasques-Nóvoa, Francisco, Nascimento, Diana S., Dmitriev, Sergey E., Gladyshev, Vadim N., Kalinichenko, Vladimir V., Logarinho, Elsa·2022·Nature Aging
DOI 10.1038/s43587-022-00209-9
Open this paper in CoChat — free account

Abstract

The FOXM1 transcription factor exhibits pleiotropic C-terminal transcriptional and N-terminal non-transcriptional functions in various biological processes critical for cellular homeostasis. We previously found that FOXM1 repression during cellular aging underlies the senescence phenotypes, which were vastly restored by overexpressing transcriptionally active FOXM1. Yet, it remains unknown whether increased expression of FOXM1 can delay organismal aging. Here, we show that in vivo cyclic induction of an N-terminal truncated FOXM1 transgene on progeroid and naturally aged mice offsets aging-associated repression of full-length endogenous Foxm1, reinstating both transcriptional and non-transcriptional functions. This translated into mitigation of several cellular aging hallmarks, as well as molecular and histopathological progeroid features of the short-lived Hutchison-Gilford progeria mouse model, significantly extending its lifespan. FOXM1 transgene induction also reinstated endogenous Foxm1 levels in naturally aged mice, delaying aging phenotypes while extending their lifespan. Thus, we disclose that FOXM1 genetic rewiring can delay senescence-associated progeroid and natural aging pathologies.

Overview

Integrity signals

Registry

Crossref · 10.1038/s43587-022-00209-9

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Cyclic expression of the transcription factor FOXM1 extends the longevity of progeroid mice and wild type mice.

    “Finally, cyclic expression of the transcription factor FOXM1 extends the longevity of progeroid mice and wild type mice 226 .”

    From Hallmarks of aging: An expanding universe (2023) · cites this paper as [226]

  • Other transcription factors might represent a safer alternative to induce epigenetic rejuvenation.

    “further supporting the idea that other transcription factors might represent a safer alternative to induce epigenetic rejuvenation as also reported by other groups 61,118 .”

    From Mechanisms, pathways and strategies for rejuvenation through epigenetic reprogramming (2023) · cites this paper as [118]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 76

  1. Kirkwood, T. B. L. Understanding the odd science of aging. Cell 120, 437–447 (2005). · DOI · Paper page
  2. Macedo, J. C., Vaz, S. & Logarinho, E. Mitotic dysfunction associated with aging hallmarks. Adv. Exp. Med. Biol. 1002, 153–188 (2017). · DOI
  3. Melo-Pereira, S., Ribeiro, R. & Logarinho, E. Approaches towards longevity: reprogramming, senolysis, and improved mitotic competence as anti-aging therapies. Int. J. Mol. Sci. 20, 938 (2019). · DOI
  4. Sieben, C. J. et al. BubR1 allelic effects drive phenotypic heterogeneity in mosaic-variegated aneuploidy progeria syndrome. J. Clin. Invest. 130, 171–188 (2020). · DOI
  5. Wan, X. et al. Identification of FoxM1–Bub1b signaling pathway as a required component for growth and survival of rhabdomyosarcoma. Cancer Res. 72, 5889–5899 (2012). · DOI
  6. Macedo, J. C. et al. FoxM1 repression during human aging leads to mitotic decline and aneuploidy-driven full senescence. Nat. Commun. 9, 2834 (2018). · DOI · Paper page
  7. Laoukili, J. et al. Activation of FoxM1 during G2 requires cyclin A/Cdk-dependent relief of autorepression by the FoxM1 N-terminal domain. Mol. Cell. Biol. 28, 3076–3087 (2008). · DOI
  8. Zona, S., Bella, L., Burton, M. J., Nestal de Moraes, G. & Lam, E. W. F. FOXM1: an emerging master regulator of DNA damage response and genotoxic agent resistance. Biochim. Biophys. Acta 1839, 1316–1322 (2014). · DOI
  9. Alvarez-Fernández, M. & Medema, R. H. Novel functions of FoxM1: from molecular mechanisms to cancer therapy. Front. Oncol. 3, 30 (2013). · DOI · Paper page
  10. Black, M. et al. FOXM1 nuclear transcription factor translocates into mitochondria and inhibits oxidative phosphorylation. Mol. Biol. Cell https://doi.org/10.1091/mbc.E19-07-0413 (2020). · DOI
  11. Limzerwala, J. F. et al. FoxM1 insufficiency hyperactivates Ect2–RhoA–mDia1 signaling to drive cancer. Nat. Cancer 1, 1010–1024 (2020). · DOI
  12. De Sandre-Giovannoli, A. et al. Lamin A truncation in Hutchinson–Gilford progeria. Science 300, 2055 (2003). · DOI · Paper page
  13. Eriksson, M. et al. Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome. Nature 423, 293–298 (2003). · DOI · Paper page
  14. Worman, H. J. & Foisner, R. The nuclear envelope from basic biology to therapy. Biochem. Soc. Trans. 38, 253–256 (2010). · DOI
  15. Ashapkin, V. V., Kutueva, L. I., Kurchashova, S. Y. & Kireev, I. I. Are there common mechanisms between the Hutchinson–Gilford progeria syndrome and natural aging? Front. Genet. 10, 455 (2019). · DOI
  16. Carrero, D., Soria-Valles, C. & López-Otín, C. Hallmarks of progeroid syndromes: lessons from mice and reprogrammed cells. Dis. Model. Mech. 9, 719–735 (2016). · DOI · Paper page
  17. Hennekam, R. C. M. Hutchinson–Gilford progeria syndrome: review of the phenotype. Am. J. Med. Genet. A 140, 2603–2624 (2006). · DOI
  18. Gordon, L. B. et al. Association of lonafarnib treatment vs no treatment with mortality rate in patients with Hutchinson–Gilford progeria syndrome. JAMA 319, 1687–1695 (2018). · DOI
  19. Gordon, L. B. et al. Impact of farnesylation inhibitors on survival in Hutchinson–Gilford progeria syndrome. Circulation 130, 27–34 (2014). · DOI
  20. Misteli, T. Farnesyltransferase inhibition in HGPS. Cell 184, 293 (2021). · DOI
  21. Davies, B. S. J. et al. An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria. Hum. Mol. Genet. 19, 2682–2694 (2010). · DOI
  22. Beyret, E. et al. Single-dose CRISPR–Cas9 therapy extends lifespan of mice with Hutchinson–Gilford progeria syndrome. Nat. Med. 25, 419–422 (2019). · DOI
  23. Santiago-Fernández, O. et al. Development of a CRISPR–Cas9-based therapy for Hutchinson–Gilford progeria syndrome. Nat. Med. 25, 423–426 (2019). · DOI
  24. Scaffidi, P. & Misteli, T. Reversal of the cellular phenotype in the premature aging disease Hutchinson–Gilford progeria syndrome. Nat. Med. 11, 440–445 (2005). · DOI · Paper page
  25. Saxena, S. & Kumar, S. Pharmacotherapy to gene editing: potential therapeutic approaches for Hutchinson–Gilford progeria syndrome. GeroScience https://doi.org/10.1007/s11357-020-00167-3 (2020). · DOI
  26. Kudlow, B. A., Stanfel, M. N., Burtner, C. R., Johnston, E. D. & Kennedy, B. K. Suppression of proliferative defects associated with processing-defective lamin A mutants by hTERT or inactivation of p53. Mol. Biol. Cell 19, 5238–5248 (2008). · DOI
  27. Wang, I. C. et al. Increased expression of FoxM1 transcription factor in respiratory epithelium inhibits lung sacculation and causes Clara cell hyperplasia. Dev. Biol. 347, 301–314 (2010). · DOI
  28. Halasi, M. & Gartel, A. L. A novel mode of FoxM1 regulation: positive auto-regulatory loop. Cell Cycle 8, 1966–1967 (2009). · DOI
  29. Musich, P. R. & Zou, Y. DNA-damage accumulation and replicative arrest in Hutchinson–Gilford progeria syndrome. Biochem. Soc. Trans. 39, 1764–1769 (2011). · DOI
  30. Zhang, W., Qu, J., Liu, G. H. & Belmonte, J. C. I. The ageing epigenome and its rejuvenation. Nat. Rev. Mol. Cell Biol. 21, 137–150 (2020). · DOI · Paper page
  31. Arancio, W., Pizzolanti, G., Genovese, S. I., Pitrone, M. & Giordano, C. Epigenetic involvement in Hutchinson–Gilford progeria syndrome: a mini-review. Gerontology 60, 197–203 (2014). · DOI
  32. Shumaker, D. K. et al. Mutant nuclear lamin A leads to progressive alterations of epigenetic control in premature aging. Proc. Natl Acad. Sci. USA 103, 8703–8708 (2006). · DOI · Paper page
  33. Benayoun, B. A., Pollina, E. A. & Brunet, A. Epigenetic regulation of ageing: linking environmental inputs to genomic stability. Nat. Rev. Mol. Cell Biol. 16, 593–610 (2015). · DOI · Paper page
  34. Fong, L. G. et al. Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice. Proc. Natl Acad. Sci. USA 101, 18111–18116 (2004). · DOI
  35. Varga, R. et al. Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson–Gilford progeria syndrome. Proc. Natl Acad. Sci. USA 103, 3250–3255 (2006). · DOI
  36. Stehbens, W. E., Delahunt, B., Shozawa, T. & Gilbert-Barness, E. Smooth muscle cell depletion and collagen types in progeric arteries. Cardiovasc. Pathol. 10, 133–136 (2001). · DOI
  37. Olive, M. et al. Cardiovascular pathology in Hutchinson–Gilford progeria: correlation with the vascular pathology of aging. Arterioscler. Thromb. Vasc. Biol. 30, 2301–2309 (2010). · DOI
  38. Wang, Y. et al. Epidermal expression of the truncated prelamin A causing Hutchinson–Gilford progeria syndrome: effects on keratinocytes, hair and skin. Hum. Mol. Genet. 17, 2357–2369 (2008). · DOI
  39. Kurban, R. S. & Bhawan, J. Histologic changes in skin associated with aging. J. Dermatol. Surg. Oncol. 16, 908–914 (1990). · DOI · Paper page
  40. Merideth, M. A. et al. Phenotype and course of Hutchinson–Gilford progeria syndrome. N. Engl. J. Med. 358, 592–604 (2008). · DOI
  41. Alam, H., Sehgal, L., Kundu, S. T., Dalal, S. N. & Vaidya, M. M. Novel function of keratins 5 and 14 in proliferation and differentiation of stratified epithelial cells. Mol. Biol. Cell 22, 4068–4078 (2011). · DOI
  42. Komutrattananont, P., Mahakkanukrauh, P. & Das, S. Morphology of the human aorta and age-related changes: anatomical facts. Anat. Cell Biol. 52, 109–114 (2019). · DOI
  43. Kim, P. H. et al. Disrupting the LINC complex in smooth muscle cells reduces aortic disease in a mouse model of Hutchinson–Gilford progeria syndrome. Sci. Transl. Med. 10, eaat7163 (2018). · DOI
  44. Turner, M. D., Nedjai, B., Hurst, T. & Pennington, D. J. Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease. Biochim. Biophys. Acta 1843, 2563–2582 (2014). · DOI
  45. Barger, C. J., Branick, C., Chee, L. & Karpf, A. R. Pan-cancer analyses reveal genomic features of FOXM1 overexpression in cancer. Cancers 11, 251 (2019). · DOI
  46. Conboy, I. M. & Rando, T. A. Aging, stem cells and tissue regeneration: lessons from muscle. Cell Cycle 4, 407–410 (2005). · DOI · Paper page
  47. Tyrrell, D. J. & Goldstein, D. R. Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6. Nat. Rev. Cardiol. 18, 58–68 (2021). · DOI
  48. Pisano, C., Balistreri, C. R., Ricasoli, A. & Ruvolo, G. Cardiovascular disease in ageing: an overview on thoracic aortic aneurysm as an emerging inflammatory disease. Mediators Inflamm. 2017, 1274034 (2017). · DOI
  49. Helske, S. et al. Complement system is activated in stenotic aortic valves. Atherosclerosis 196, 190–200 (2008). · DOI
  50. Wiedmer, P. et al. Sarcopenia–molecular mechanisms and open questions. Ageing Res. Rev. 65, 101200 (2021). · DOI
  51. Koves, T. R. et al. Mitochondrial overload and incomplete fatty-acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 7, 45–56 (2008). · DOI · Paper page
  52. Li, X. et al. Direct and indirect effects of growth hormone receptor ablation on liver expression of xenobiotic metabolizing genes. Am. J. Physiol. 305, E942–E950 (2013).
  53. Mu, X. et al. Cytoskeleton stiffness regulates cellular senescence and innate immune response in Hutchinson–Gilford Progeria Syndrome. Aging Cell 19, e13152 (2020). · DOI
  54. Rovillain, E. et al. Activation of nuclear factor-kappa B signalling promotes cellular senescence. Oncogene 30, 2356–2366 (2011). · DOI
  55. Prokocimer, M., Barkan, R. & Gruenbaum, Y. Hutchinson–Gilford progeria syndrome through the lens of transcription. Aging Cell 12, 533–543 (2013). · DOI
  56. Sun, S. et al. Vascular endothelium–targeted Sirt7 gene therapy rejuvenates blood vessels and extends lifespan in a Hutchinson–Gilford progeria model. Sci. Adv. 6, eaay5556 (2020). · DOI
  57. Yu, W. et al. Silencing forkhead box M1 promotes apoptosis and autophagy through SIRT7/mTOR/IGF2 pathway in gastric cancer cells. J. Cell. Biochem. 119, 9090–9098 (2018). · DOI
  58. Paez‐Ribes, M., González‐Gualda, E., Doherty, G. J. & Muñoz‐Espín, D. Targeting senescent cells in translational medicine. EMBO Mol. Med. 11, e10234 (2019). · DOI · Paper page
  59. Maloberti, A. et al. Vascular aging and disease of the large vessels: role of inflammation. High Blood Press. Cardiovasc. Prev. 26, 175–182 (2019). · DOI
  60. Ferreira, F. J., Carvalho, L., Logarinho, E. & Bessa, J. foxm1 modulates cell non-autonomous response in Zebrafish skeletal muscle homeostasis. Cells 10, 1241 (2021). · DOI
  61. Hou, Y. et al. The transcription factor Foxm1 is essential for the quiescence and maintenance of hematopoietic stem cells. Nat. Immunol. 16, 810–818 (2015). · DOI
  62. Chen, Z. et al. A Cdh1–Foxm1–Apc axis controls muscle development and regeneration. Cell Death Dis. 11, 180 (2020). · DOI
  63. Anisimov, V. N. Lifespan extension and cancer risk: myths and reality. Exp. Gerontol. 36, 1101–1136 (2001). · DOI
  64. Sotillo, R. et al. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 11, 9–23 (2007). · DOI · Paper page
  65. Ustiyan, V. et al. FOXF1 transcription factor promotes lung morphogenesis by inducing cellular proliferation in fetal lung mesenchyme. Dev. Biol. 443, 50–63 (2018). · DOI
  66. Kalinichenko, V. V. et al. Ubiquitous expression of the forkhead box M1B transgene accelerates proliferation of distinct pulmonary cell types following lung injury. J. Biol. Chem. 278, 37888–37894 (2003). · DOI
  67. Laws, N. & Hoey, A. Progression of kyphosis in mdx mice. J. Appl. Physiol. 97, 1970–1977 (2004). · DOI
  68. Papp, A. C. et al. AmpliSeq transcriptome analysis of human alveolar and monocyte-derived macrophages over time in response to Mycobacterium tuberculosis infection. PLoS ONE13, e0198221 (2018). · DOI
  69. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013). · DOI · Paper page
  70. Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010). · DOI · Paper page
  71. McCarthy, D. J., Chen, Y. & Smyth, G. K. Differential expression analysis of multifactor RNA-seq experiments with respect to biological variation. Nucleic Acids Res. 40, 4288–4297 (2012). · DOI · Paper page
  72. Ritchie, M. E. et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015). · DOI · Paper page
  73. Yu, G., Wang, L. G., Han, Y. & He, Q. Y. ClusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284–287 (2012). · DOI · Paper page
  74. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929–1935 (2006). · DOI · Paper page
  75. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 57, 289–300 (1995). · DOI · Paper page
  76. Sampaio-Pinto, V. et al. Neonatal apex resection triggers cardiomyocyte proliferation, neovascularization and functional recovery despite local fibrosis. Stem Cell Reports 10, 860–874 (2018). · DOI

Cited by

Sorted by citations

Metadata

Authors
Ribeiro, R., Macedo, J. C., Costa, M., Ustiyan, V., Shindyapina, A. V., Tyshkovskiy, A., Gomes, R. N., Castro, J. P., Kalin, T. V., Vasques-Nóvoa, F., Nascimento, D. S., Dmitriev, S. E., Gladyshev, V. N., Kalinichenko, V. V., & Logarinho, E.
ORCID
Venue
Nature Aging
Publisher
Springer Science and Business Media LLC
Published
2022-05-05
Volume
2
Issue
5
Pages
397-411
ISSN
2662-8465
DOI
10.1038/s43587-022-00209-9
Cited by
60
References
15
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review